Frits H.A.F. de Man

1.6k total citations
38 papers, 1.1k citations indexed

About

Frits H.A.F. de Man is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Frits H.A.F. de Man has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Surgery, 30 papers in Cardiology and Cardiovascular Medicine and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Frits H.A.F. de Man's work include Coronary Interventions and Diagnostics (31 papers), Cardiac Valve Diseases and Treatments (15 papers) and Antiplatelet Therapy and Cardiovascular Diseases (13 papers). Frits H.A.F. de Man is often cited by papers focused on Coronary Interventions and Diagnostics (31 papers), Cardiac Valve Diseases and Treatments (15 papers) and Antiplatelet Therapy and Cardiovascular Diseases (13 papers). Frits H.A.F. de Man collaborates with scholars based in Netherlands, Greece and United States. Frits H.A.F. de Man's co-authors include Clemens von Birgelen, Martin G. Stoel, Gerard C.M. Linssen, Marije M. Löwik, K. Gert van Houwelingen, J. W. Louwerenburg, Kenneth Tandjung, Hanim Sen, Carine J.M. Doggen and Mounir W.Z. Basalus and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Frits H.A.F. de Man

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frits H.A.F. de Man Netherlands	17	932	756	290	281	72	38	1.1k
Marc Hartmann Netherlands	18	936 1.0×	698 0.9×	333 1.1×	289 1.0×	63 0.9×	49	1.1k
Knud Nørregaard Hansen Denmark	19	784 0.8×	695 0.9×	319 1.1×	250 0.9×	26 0.4×	40	1.0k
John Ormiston New Zealand	21	1.4k 1.5×	1.1k 1.5×	424 1.5×	462 1.6×	65 0.9×	32	1.6k
Luis S. Díaz de la Llera Spain	15	546 0.6×	690 0.9×	215 0.7×	161 0.6×	35 0.5×	41	865
Samuel J. DeMaio United States	8	1.1k 1.2×	853 1.1×	365 1.3×	374 1.3×	50 0.7×	12	1.4k
K. Gert van Houwelingen Netherlands	18	1.1k 1.2×	858 1.1×	355 1.2×	362 1.3×	27 0.4×	57	1.2k
Wanlin Yeh United States	13	841 0.9×	819 1.1×	509 1.8×	179 0.6×	49 0.7×	21	1.1k
Kentaro Okamatsu Japan	17	772 0.8×	420 0.6×	402 1.4×	364 1.3×	46 0.6×	35	957
Patrick M.J. Verhorst Netherlands	13	542 0.6×	688 0.9×	250 0.9×	202 0.7×	20 0.3×	34	902
Aamir Javaid United States	15	462 0.5×	457 0.6×	262 0.9×	110 0.4×	33 0.5×	32	709

Countries citing papers authored by Frits H.A.F. de Man

Since Specialization

Citations

This map shows the geographic impact of Frits H.A.F. de Man's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frits H.A.F. de Man with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frits H.A.F. de Man more than expected).

Fields of papers citing papers by Frits H.A.F. de Man

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frits H.A.F. de Man. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frits H.A.F. de Man. The network helps show where Frits H.A.F. de Man may publish in the future.

Co-authorship network of co-authors of Frits H.A.F. de Man

This figure shows the co-authorship network connecting the top 25 collaborators of Frits H.A.F. de Man. A scholar is included among the top collaborators of Frits H.A.F. de Man based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frits H.A.F. de Man. Frits H.A.F. de Man is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buiten, Rosaly A., Eline H. Ploumen, Paolo Zocca, et al.. (2020). Three contemporary thin‐strut drug‐eluting stents implanted in severely calcified coronary lesions of participants in a randomized all‐comers trial. Catheterization and Cardiovascular Interventions. 96(5). E508–E515. 11 indexed citations

Zocca, Paolo, Marlies M. Kok, Kenneth Tandjung, et al.. (2018). 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents. JACC: Cardiovascular Interventions. 11(5). 462–469. 34 indexed citations

Zocca, Paolo, Marlies M. Kok, Liefke C. van der Heijden, et al.. (2018). High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. International Journal of Cardiology. 268. 11–17. 14 indexed citations

Kok, Marlies M., Liefke C. van der Heijden, Hanim Sen, et al.. (2016). Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. JACC: Cardiovascular Interventions. 9(6). 553–561. 10 indexed citations

Heijden, Liefke C. van der, Marlies M. Kok, Hans W. Louwerenburg, et al.. (2016). Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes. Journal of Cardiology. 69(4). 660–665. 20 indexed citations

Löwik, Marije M., Ming Kai Lam, Hanim Sen, et al.. (2015). Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial. EuroIntervention. 10(11). 1276–1279. 12 indexed citations

Sen, Hanim, Ming Kai Lam, Marije M. Löwik, et al.. (2015). Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents. JACC: Cardiovascular Interventions. 8(7). 889–899. 34 indexed citations

Sen, Hanim, Ming Kai Lam, Kenneth Tandjung, et al.. (2014). Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and Non-Enrolled TWENTE registry. International Journal of Cardiology. 176(3). 885–890. 8 indexed citations

Lam, Ming Kai, Hanim Sen, K. Gert van Houwelingen, et al.. (2014). Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial. American Heart Journal. 169(1). 69–77. 15 indexed citations

10.

Sen, Hanim, Ming Kai Lam, Kenneth Tandjung, et al.. (2014). Complex patients treated with zotarolimus‐eluting resolute and everolimus‐eluting xience V stents in the randomized TWENTE trial: Comparison of 2‐year clinical outcome. Catheterization and Cardiovascular Interventions. 85(1). 74–81. 7 indexed citations

11.

Jørstad, H T, Bjorn de Wagenaar, Frits H.A.F. de Man, et al.. (2014). Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function. EuroIntervention. 10(7). 784–791. 8 indexed citations

12.

Tandjung, Kenneth, Mounir W.Z. Basalus, Hanim Sen, et al.. (2013). Women treated with second‐generation zotarolimus‐eluting resolute stents and everolimus‐eluting xience V stents: insights from the gender‐stratified, randomized, controlled TWENTE trial. Catheterization and Cardiovascular Interventions. 82(3). 396–405. 5 indexed citations

13.

Tandjung, Kenneth, Hanim Sen, Ming Kai Lam, et al.. (2013). Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents. Journal of the American College of Cardiology. 61(24). 2406–2416. 56 indexed citations

14.

Sen, Hanim, Kenneth Tandjung, Mounir W.Z. Basalus, et al.. (2012). Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents. EuroIntervention. 8(6). 664–671. 16 indexed citations

15.

Hartmann, Marc, Gary S. Mintz, Gert K. van Houwelingen, et al.. (2011). Impact of analyzing fewer image frames per segment during offline volumetric radiofrequency-based intravascular ultrasound measurements of target lesions prior to percutaneous coronary interventions. International journal of cardiac imaging. 28(3). 479–489. 1 indexed citations

16.

Tandjung, Kenneth, Mounir W.Z. Basalus, Hans W. Louwerenburg, et al.. (2011). Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first‐ and second‐generation drug‐eluting stents. Catheterization and Cardiovascular Interventions. 80(4). 524–530. 8 indexed citations

17.

Jonkers, I.J.A.M., A.H.M. Smelt, Hiroaki Hattori, et al.. (2003). Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG. Journal of Lipid Research. 44(8). 1462–1469. 32 indexed citations

18.

Man, Frits H.A.F. de, Arnoud van der Laarse, Hans Jansen, et al.. (2000). The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis. 153(2). 363–371. 16 indexed citations

19.

Man, Frits H.A.F. de, et al.. (1998). Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase. Atherosclerosis. 136(2). 255–262. 20 indexed citations

20.

Kock, L A, et al.. (1996). In vitro lipolysis of human VLDL: Effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Atherosclerosis. 121(1). 75–84. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact